Other drugs in this group registered in Europe for the treatment of type 2 diabetes in monotherapy or combination treatment are canagliflozin (Invokana®, 2013) [105], empagliflozin (Jardiance®, 2014) [106], and ertugliflozin (Steglatro®, 2017) [107], and a drug registered for the treatment of type 1 diabetes as a supplement to insulin therapy is sotagliflozin (Zynquista®, 2019) [108]. Here, INS is linked to type 2 diabetes mellitus.